Plasma Therapy Market to Projected to Reach US$ 1,097.64 million by 2030

The plasma therapy market is expected to grow from US$ 390.25 million in 2022 to US$ 1,097.64 million by 2030; the market is estimated to register a CAGR of 13.80% from 2022 to 2030. Key factors driving the market growth include the rising cases of orthopedic disorders in people, especially in the geriatric population, the rising number of joint and muscle injuries in athletes, and the surging demand for minimally invasive cosmetic procedures.

 

Platelet-rich plasma (PRP) is a form of regenerative medicine that amplifies natural growth factors in blood to heal tissue. It entails the utilization of the blood plasma obtained from individuals who have successfully recovered from an illness to address the range of medical conditions and foster the process of healing. PRP treatments find applications in orthopedics for the treatment of joint injuries, dermatology in skin rejuvenation procedures, and dentistry for tissue repair .

Download Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00004429/

Market Opportunity

Use of PRP in Combination Therapies

PRP therapy is an evolving treatment method with several applications in dermatology, particularly for hair restoration, skin rejuvenation, acne scars, dermal augmentation, and striae distensae. Using PRP together with laser therapies, microneedling, dermal fillers, and autologous fat grafting can result in better aesthetic outcomes due to synergistic effects. However, there is a need for standardization of PRP treatment protocols for specific conditions. PRP has great potential in dermatology, and its therapeutic applications are continuously expanding. Many studies have been conducted to assess the effect of PRP in combined medical therapy for various dermatological disorders such as androgenetic alopecia, vitiligo, and skin rejuvenation. For instance, a study, “Evaluation of adding platelet-rich plasma to combined medical therapy in androgenetic alopecia,” published by PubMed Central in 2021, was carried out on 126 patients suffering from Androgenetic alopecia (AGA), a common hair loss disorder, the study concluded that the integration of “PRP with micro-needling” to the combined medical therapy in AGA boosts its efficacy and reduces the time required for maximum improvement.

Similarly, in another article published by Wiley Online Library in November 2020, a study was carried out to assess various combination therapy strategies for treating vitiligo. The study included eleven studies with 670 cases. It concluded that in comparison to monotherapy, the clinical improvement of re-pigmentation was significantly higher when using a combination of 308-nm excimer laser and PRP. Similarly, a combination of fractional carbon dioxide laser and PRP resulted in a higher mean improvement grade of re-pigmentation.

Therefore, the introduction of PRP-combination therapies is creating various opportunities in the plasma therapy market.

SEGMENTAL OVERVIEW

The plasma therapy market is segmented on the basis of type, source, application, end product, and end user. In terms of type, the market is segmented into pure PRP, leukocyte-rich PRP, pure platelet-rich fibrin, and leukocyte-rich fibrin. The pure platelet-rich fibrin segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022–2030. Leukocyte-rich PRP (LR-PRP) is a type of PRP that has a higher concentration of neutrophils (white blood cells) than the baseline level. It is generally associated with proinflammatory effects. However, in some cases, LR-PRP can be beneficial to stimulate inflammation in the body to indicate a chronic condition such as tendinopathy.

The plasma therapy market, by source, is bifurcated into autologous and allogeneic. The autologous segment dominated the market in 2022, and the allogeneic segment is anticipated to record a higher CAGR during 2022–2030. Autologous PRP injection is a secure and reliable biological technique that is used for the treatment of different musculoskeletal disorders. PRP injection can effectively support the primary treatment of patients with chronic autoimmune inflammatory diseases such as rheumatoid arthritis by suppressing the production of inflammatory cytokines and promoting the growth of synovial fibroblasts.

 

 

About Us:

The Insight Partners is a market research solution and consultation company. Specializing in syndicate market research, our team helps clients in their hunt for revenue pockets in several industries. A team of 250+ research experts is dedicated to offering the most relevant, data-driven, and trustworthy market insights and consultation.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us

The Insight Partners

Phone: +1-646-491-9876

E-mail: [email protected]

About Author